Determinants of disability in multiple sclerosis at various disease stages: A multiparametric magnetic resonance study

Archives of Neurology

Volumn 64, Issue 8, 2007, Pages 1163-1168

  Pulizzi, Annalisa ^a   Rovaris, Marco ^a   Judica, Elda ^a   Sormani, Maria Pia ^a,b   Martinelli, Vittorio ^a   Comi, Giancarlo ^a   Filippi, Massimo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

N ACETYLASPARTIC ACID;

ADULT; ANISOTROPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSION TENSOR IMAGING; DISABILITY; DISEASE DURATION; FEMALE; GRAY MATTER; HUMAN; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

ADULT; AGED; ANISOTROPY; ASPARTIC ACID; BRAIN; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DIFFUSION MAGNETIC RESONANCE IMAGING; DISABILITY EVALUATION; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NERVOUS SYSTEM DISEASES; PERIAQUEDUCTAL GRAY; SYNDROME; TIME FACTORS;

EID: 34147186928     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.64.8.1163     Document Type: Article

References (36)

1. Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol. 2002;15(3):239-245.
2. Miller DH, Thompson AJ, Filippi M. Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. J Neurol. 2003;250(12):1407-1419.
3. Rovaris M, Filippi M. "Importance sampling": a strategy to overcome the clinical/MRI paradox in MS? J Neurol Sci. 2005;237(1-2):1-3.
4. 1H-MRS quantification of tNA and tCr in patients with multiple sclerosis: a meta-analytic review. Brain. 2005;128(pt 11):2483-2506.
5. Gonen O, Viswanathan AK, Catalaa I, Babb J, Udupa J, Grossman RI. Total brain N-acetylaspartate concentration in normal, age-grouped females: quantitation with non-echo proton NMR spectroscopy. Magn Reson Med. 1998;40(5):684-689.
6. Ge Y, Gonen O, Inglese M, Babb JS, Markowitz CE, Grossman RI. Neuronal cell injury precedes brain atrophy in multiple sclerosis. Neurology. 2004;62(4):624-627.
7. Rovaris M, Gass A, Bammer R, et al. Diffusion MRI in multiple sclerosis. Neurology. 2005;65(10):1526-1532.
8. Mainero C, De Stefano N, Iannucci G, et al. Correlates of MS disability assessed in vivo using aggregates of MR quantities. Neurology. 2001;56(10):1331-1334.
9. Wolinsky JS, Narayana PA, Noseworthy JH, et al. Linomide in relapsing and secondary progressive MS, part II: MRI results. Neurology. 2000;54(9):1734-1741.
10. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol. 2005;58(6):840-846.
11. Lublin FD, Reingold SC; National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46(4):907-911.
12. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983;33(11):1444- 1452.
13. Rovaris M, Filippi M, Calori G, et al. Intra-observer reproducibility in measuring new putative MR markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images. J Neurol. 1997;244(4):266-270.
14. Rovaris M, Judica E, Gallo A, et al. Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years. Brain. 2006;129(pt 10):2628-2634.
15. Filippi M, Cercignani M, Inglese M, Horsfield MA, Comi G. Diffusion tensor magnetic resonance imaging in multiple sclerosis. Neurology. 2001;56(3):304-311.
16. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129(pt 3):606-616.
17. Rovaris M, Gambini A, Gallo A, et al. Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution. Neurology. 2005;65(10):1626-1630.
18. Rosso C, Remy P, Creange A, Brugieres P, Cesaro P, Hosseini H. Diffusion-weighted MR imaging characteristics of an acute strokelike form of multiple sclerosis. AJNR Am J Neuroradiol. 2006;27(5):1006-1008.
19. Filippi M, Inglese M, Rovaris M, et al. Magnetization transfer imaging to monitor the evolution of MS: a 1-year follow-up study. Neurology. 2000;55(7):940-946.
20. Tortorella C, Viti B, Bozzali M, et al. A magnetization transfer histogram study of normal-appearing brain tissue in MS. Neurology. 2000;54(1):186-193.
21. Chard DT, Griffin CM, McLean MA, et al. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain. 2002;125(pt 10):2342-2352.
22. De Stefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol. 2001;58(1):65-70.
23. Agosta F, Rovaris M, Pagani E, Sormani MP, Comi G, Filippi M. Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain. 2006;129(pt 10):2620-2627.
24. Vrenken H, Geurts JJ, Knol DL, et al. Whole-brain T1 mapping in multiple sclerosis: global changes of normal-appearing gray and white matter. Radiology. 2006;240(3):811-820.
25. Vrenken H, Pouwels PJ, Geurts JJ, et al. Altered diffusion tensor in multiple sclerosis normal-appearing brain tissue: cortical diffusion changes seem related to clinical deterioration. J Magn Reson Imaging. 2006;23(5):628-636.
26. Adalsteinsson E, Langer-Gould A, Homer RJ, et al. Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol. 2003;24(10):1941-1945.
27. Chen JT, Narayanan S, Collins DL, Smith SM, Matthews PM, Arnold DL. Relating neocortical pathology to disability progression in multiple sclerosis using MRI. Neuroimage. 2004;23(3):1168-1175.
28. Geurts JJ, Bo L, Pouwels PJ, Castelijns JA, Polman CH, Barkhof F. Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol. 2005;26(3):572-577.
29. Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol. 2001;50(3):389-400.
30. Evangelou N, Konz D, Esiri MM, Smith S, Palace J, Matthews PM. Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. Brain. 2000;123(pt 9):1845-1849.
31. Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol. 2006;5(4):343-354.
32. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain. 2003;126(pt 4):770-782.
33. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005;128(pt 11):2705-2712.
34. Lycklama G, Thompson A, Filippi M, et al. Spinal-cord MRI in multiple sclerosis. Lancet Neurol. 2003;2(9):555-562.
35. Rocca MA, Colombo B, Falini A, et al. Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes. Lancet Neurol. 2005;4(10):618-626.
36. Rudick RA, Lee JC, Simon J, Fisher E. Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study. Ann Neurol. 2006;60(2):236-242.